Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.
[1] It binds to LOXL2 and acts as an immunomodulator.
[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.
This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.